Neoadjuvant chemotherapy prior to radical cystectomy for muscle‐invasive bladder cancer with variant histology

Neoadjuvant chemotherapy in pure urothelial bladder cancer provides a significant survival benefit. However, to the authors' knowledge, it is unknown whether this benefit persists in histological variants. The objective of the current study was to assess the effect of neoadjuvant chemotherapy on the probability of non‐organ‐confined disease and overall survival after radical cystectomy (RC) in patients with histological variants.

[1]  Ahmed Kamel,et al.  Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[2]  R. Bernards,et al.  ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy. , 2016, European urology.

[3]  J. Pow-Sang,et al.  Clinical Outcomes After Neoadjuvant Chemotherapy and Radical Cystectomy in the Presence of Urothelial Carcinoma of the Bladder With Squamous or Glandular Differentiation. , 2016, Clinical genitourinary cancer.

[4]  K. Guru,et al.  Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma. , 2016, Clinical Genitourinary Cancer.

[5]  E. Plimack,et al.  Advanced small cell carcinoma of the bladder: clinical characteristics, treatment patterns and outcomes in 960 patients and comparison with urothelial carcinoma , 2015, Cancer medicine.

[6]  K. Moon,et al.  Impact of Squamous and Glandular Differentiation on Oncologic Outcomes in Upper and Lower Tract Urothelial Carcinoma , 2014, PloS one.

[7]  S. Boorjian,et al.  Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  P. Kantoff,et al.  Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  I. Sinescu,et al.  Comparative study of conventional urothelial carcinoma, squamous differentiation carcinoma and pure squamous carcinoma in patients with invasive bladder tumors , 2014, Journal of medicine and life.

[10]  Anirban P. Mitra,et al.  Does presence of squamous and glandular differentiation in urothelial carcinoma of the bladder at cystectomy portend poor prognosis? An intensive case-control analysis. , 2014, Urologic oncology.

[11]  R. Shah,et al.  Variant (divergent) histologic differentiation in urothelial carcinoma is under-recognized in community practice: impact of mandatory central pathology review at a large referral hospital. , 2013, Urologic oncology.

[12]  S. Porten,et al.  Should histologic variants alter definitive treatment of bladder cancer? , 2013, Current opinion in urology.

[13]  A. Giobbie-Hurder,et al.  Challenges of guarantee-time bias. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  B. Bochner,et al.  Pathological response to neoadjuvant chemotherapy for muscle‐invasive micropapillary bladder cancer , 2013, BJU international.

[15]  David A. Green,et al.  Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy. , 2013, European journal of cancer.

[16]  J. Chin,et al.  Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer. , 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[17]  T. Powles,et al.  Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle‐invasive transitional cell carcinoma of the bladder , 2012, Cancer.

[18]  E. Messing,et al.  DO MIXED HISTOLOGICAL FEATURES AFFECT SURVIVAL BENEFIT FROM NEOADJUVANT PLATINUM‐BASED COMBINATION CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED BLADDER CANCER? , 2011, BJU international.

[19]  J. Bellmunt,et al.  Variant Forms of Bladder Cancer: Basic Considerations on Treatment Approaches , 2011, Current oncology reports.

[20]  E. Messing,et al.  Do mixed histological features affect survival benefit from neoadjuvant platinum‐based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group‐Directed Intergroup Study (S8710) , 2010, BJU international.

[21]  Mahul B Amin,et al.  Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications , 2009, Modern Pathology.

[22]  E. Vardar.  Histologic variants of infiltrating urothelial carcinoma. , 2008, Archives of pathology & laboratory medicine.

[23]  C. Dinney,et al.  Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder. , 2007, The Journal of urology.

[24]  B. Czerniak,et al.  Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder , 2007, Cancer.

[25]  J. Ro,et al.  Histologic variants of infiltrating urothelial carcinoma. , 2007, Archives of pathology & laboratory medicine.

[26]  H. Wiśniewska,et al.  Muscle-invasive urothelial cell carcinoma of the human bladder: multidirectional differentiation and ability to metastasize. , 2007, Human pathology.

[27]  H. Grossman,et al.  Neoadjuvant chemotherapy for bladder cancer , 2006, World Journal of Urology.

[28]  Z. Wolski,et al.  Usefulness of histologic homogeneity estimation of muscle-invasive urinary bladder cancer in an individual prognosis: a mapping study. , 2005, Urology.

[29]  H. V. van Boven,et al.  Small cell carcinoma of bladder: a single-center prospective study of 25 cases treated in analogy to small cell lung cancer. , 2005, Urology.

[30]  R. Millikan,et al.  Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience. , 2004, The Journal of urology.

[31]  C. Sternberg,et al.  Neo-adjuvant chemotherapy in invasive bladder cancer , 2001, World Journal of Urology.

[32]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[33]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[34]  C. Dinney,et al.  The impact of variant histology on the outcome of bladder cancer treated with curative intent. , 2009, Urologic oncology.

[35]  Joon-Oh Park,et al.  Palliative chemotherapy for non-transitional cell carcinomas of the urothelial tract , 2009, Medical oncology.

[36]  H. Grossman,et al.  Outcome of patients with bladder cancer with pN+ disease after preoperative chemotherapy and radical cystectomy. , 2009, Urology.

[37]  B. Czerniak,et al.  Review of the M.D. Anderson experience in the treatment of bladder sarcoma. , 2007, Urologic oncology.

[38]  A. Billis,et al.  Squamous and/or glandular differentiation in urothelial carcinoma: Prevalence and significance in transurethral resections of the bladder , 2004, International Urology and Nephrology.

[39]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.